The prevailing paradigm of locoregional chemotherapy has been centred around delivering chemotherapy as close to the tumour as possible and in some cases incorporating vascular isolation techniques. Strategically, the development of these techniques has been rudimentary without consideration for the interdependencies between macrovascular manipulation and the microvascular effects. This review focuses on how new capabilities offered by recent advances in vascular access technology could be exploited to facilitate the mass fluid transfer (MFT) of anticancer agents to solid tumours. A haemodynamic model of MFT is proposed using the physical laws of fluid flow, flux, and diffusion that describe the microvascular effects anticancer agents may have upon tumours through the manipulation of macrovascular blood flow control. Finally, the possible applications of this technique for several organs are discussed.
Introduction
The solid tumour microenvironment presents a major impediment to the delivery of chemotherapy. The physical barriers of high intrafluid pressure, chaotic high resistance vascular anatomy and dense extracellular matrix combined with multiple molecular point mutations produce a formidable array of tumour defences [1] [2] [3] . Direct intravital real time flow imaging has shown minimal or no blood flow in most of the tumour mass [4] . In some cases, it has been shown that < 1% of the infused chemotherapy actually reaches the tumour with the remainder accumulating in the normal tissue [5, 6] . Hence the motivation to develop a locoregional vascular chemotherapy delivery system to address these challenges.
The oncological literature abounds with reports of locoregional intra-arterial (IA) chemotherapy delivery confirming improved response rates, resection capability and better long term survival [7] [8] [9] . However, this method has not achieved universal acceptance as a first line of treatment because of technical difficulties relating to catheter dislodgement, migration and thrombosis. This is compounded by the need for laparotomy for device insertion [8] [9] [10] . In many applications of IA delivery, the chemotherapy undergoes venous recirculation, creating dose limitations. Venous chemofiltration systems were developed to circumvent this issue but were limited by a 77% filter extraction efficiency and also introduced additional morbidities associated with repeated cannulation of the venous filtration catheter [11] . Even the second-generation filters currently available are unable to prevent systemic toxicity [12] .
To address these difficulties, a universal access system has been developed ( Fig. 1) . IA, stopflow, super-selective infusions, filtration, hyperperfusion as well as IV can be performed through the same system. The device is a large bore implantable conduit capable of six simultaneously independently steerable catheters or balloons. All of the solid organs can be repeatedly isolated from a single point source [13] . The device is transcutaneous and is plugged after use so that no catheters remain intra-vascularly and thereby reducing risks. Patients can return home after the isolated infusion. The value of the system has been potentiated with improvements in resolution, radiation reduction, and versatility of modern X-ray fluoroscopy. This, in addition to new steerable radiopaque microcatheters and sheaths, ensures maximum chemotherapy delivery. The trilogy of radiological technique, microcatheter anatomical super-selection capability, and universal access have allowed manipulation of the basic physical laws governing fluid transport across porous membranes: Starlings equations, Fick's second order diffusion law, Darcy's equations governing movement of particles https://doi.org/10.1016/j.jconrel.2018. 10 .019 Received 16 July 2018; Received in revised form 15 October 2018; Accepted 15 October 2018 through porous membranes, and Poiseuille's blood flow equation (Table 1) .
The chemotherapy delivery challenge; a vascular conundrum
Starling's perfusion laws can be applied to small (< 2 mm) tumours with "normal" vascular inflow/outflow parameters (Fig. 2a) . In larger tumours however, overexpression of vascular endothelial growth factor [14, 15] results in malformed, tortuous, irregular diameter vessels and inappropriate variable distribution unrelated to metabolic demands. The high vascular resistance results in lower capillary pressure (P c ) (Fig. 2c) . The intravascular-to-extravascular pressure gradient (ΔP) is further compromised by an increase in interstitial fluid pressure (P i ) related to increased membrane permeability to proteins and fluids. The interstitial oncotic force (π i ) is further augmented by protein liberation by tumour lysis related to ischaemia and chemotherapy. At the venous end of the tumour vascular bed the filtration pressure remains low but the intravascular oncotic pressure (π c ) remains normal. Hence reabsorption of chemotherapy is augmented resulting in the worst possible combination of poor chemotherapy penetration and negligible retention (Fig. 2c) .
Mass fluid transfer
Mass fluid transfer (MFT) is defined as the delivery of soluble molecules across semipermeable membranes. Bulk fluid flux is a process used by lipid insoluble proteins to cross the capillary endothelium. The principles have been demonstrated with 57 infusions in 10 patients with secondary colorectal metastases in the liver [13] . The methods of chemotherapy delivery using vascular isolation MFT consisted of six basic components:
1. Balloon occlusion of the arterial inflow 2. Balloon occlusion of the collateral flow affecting the target organ with documentation of establishment of zero or minimal flow (below critical capillary closing pressure) 3. Washing out and removal of red blood cells and protein into the venous circulation. 4. Obstruction of the outflow via venous occlusion via balloons, gravitational forces, positive end-expiratory pressure (PEEP) and or tourniquet. 5. Vascular tumour volume replacement with high concentration chemotherapy at supra-systolic pressures. 6. Continued obstruction to venous outflow for several minutes following re-establishment of arterial inflow.
A summary of the pathophysiological response is summarised in Table 1 .
Intermittent interruption of blood supply
The demonstrated unstable vascular tumour supply [4] has rate limiting metabolic effects supplying all nutrients to rapidly dividing cells. The "Warburg effect" [16] relates to the tumour cells preferring anaerobic glycolysis rather than mitochondrial energy production. The fermentation process is inefficient (produces 2 versus 38 molecules of adenosine triphosphate per glucose molecule) and is toxic, inducing lactic acidosis that continues even in the presence of abundant oxygen [16] . However, the anaerobic glycolysis is 10 times faster and requires a smaller number of enzymes and amino acids for application. Darwinian selection favours cells equipped to survive intermittent interruption of blood supply.
MFT takes advantage of the increased endothelial permeability associated with lactic acidosis during the hypoxic phase. There is maximum cellular chemotherapy incorporation during the reactive Fig. 1 . The universal access system (a) with a multicatheter access port (b). Table 1 Basic physical laws governing fluid transport across semipermeable membranes and capillary beds. The effects of mass fluid transfer on the multiple variables.
Physical law
Variables Mass fluid transfer effect
Increased due to ischaemia P c = capillary pressure Initially decreased then increased with flow P i = interstitial pressure Increased ∇ = resorption coefficient Zero; no protein π c = intravascular oncotic pressure Zero; no protein π i = interstitial oncotic pressure Increased; tumour lysis Poiseuille's Law 
Supra-systolic perfusion
The clinical equivalent of supra-systolic perfusion is systemic hypertension. Locoregional hyperperfusion using the same universal access device has been shown to be able to drive blood flow through highly-resistant capillary beds to achieve adequate perfusion in pregangrenous tissues affected by ischemic vascular disease [17, 18] . The system is capable of delivering 8 times the resting flowrate with pressures up to 300 mm Hg. In the setting of chemotherapy delivery, the aim is to overcome the high vascular resistance, high interstitial fluid pressure and the dense desmoplastic matrix. The supra-systolic perfusion advantage is also aided by ischaemic vasodilatation, negligible infusion viscosity and bolus delivery all combining to increase chemotherapy flow into the interstitial tissue.
Removal of plasma protein and red blood cells' from the tumour vasculature
The systemic equivalent of the removal of plasma protein is nephrotic syndrome or ascites. The normal intravascular oncotic pressure is 28 mm Hg, mostly due to albumen. Washing out of intravascular protein increases the extravascular net flux (Fig. 2c-d) by a similar force, adding the hypertensive inflow pressure to the total transmural gradient. At the venous capillary end, re-absorption of fluid is essentially impossible (π c = 0). In tumours with elevated interstitial fluid pressure (IFP) the net result is to further increase the IFP but chemotherapy reabsorption will occur only with reconstitution of normal venous oncotic flow.
Protein and red blood cell binding of chemotherapeutic agents render significant concentrations of the drug inactive when given systemically. Direct infusions improve the active drug component. Table 2 provides a summary of the protein binding of the commonly used therapeutic agents used to treat solid neoplasia. Agents eventually entering the systemic circulation become bound and hence neutralised, protecting sensitive tissue. The net effect is to maximise therapeutic agent efficiency locoregionally and minimising systemic side effects remotely.
Venous outflow obstruction
The clinical equivalent of venous outflow obstruction is deep venous thrombosis or phlegmasia cerulea dolens in its more extreme presentation [22] . The haemodynamic effects of increased venous pressure are increased intravascular to interstitial fluid transfer and low re-absorption ( Fig. 2c-d) [23] . As the interstitial pressure rises, the lymphatic pressure and flow increase to compensate for the increased extravascular volume. The degree of obstruction to the main axial venous flow and collateral flow varies according to the site of the venous return. There are various techniques available to control flow in the axial venous system such as endovenous obstructing balloons, gravity (Trendelenburg/Anti-trendelenburg), PEEP as well as tourniquets. To maximise chemotherapy delivery, the outflow obstruction is maintained following resumption of arterial inflow hence improving the area under the time/concentration curve (AUC) beyond the ischemic time and allowing slow release of residual unabsorbed chemotherapy into the systemic circulation. This technique optimises gradual chemotherapy plasma binding and hence minimising side effects.
The haemodynamic model of MFT in tumours
In small tumours (< 2.5 mm) the vascular resistance, hydraulic conductance and reabsorption coefficient are normal and hence flux, nutrition and oxygenation are normal ( Fig. 2a-b) . Removing the protein, increasing the perfusion pressure and increasing the venous outflow pressure increases the arterial flux from 12 to 50 mm Hg i.e. four times the delivery gradients. On the venous side of the capillary bed, a small increase in perfusion pressure (4 mm Hg) and PEEP (16 mm Hg) leads to reabsorption changing from −12 to +36 mm Hg i.e. four times retention. The AV gradient is 14 mm Hg indicating minimal systemic leakage (Fig. 2b) [24] . In solid tumours there is increased permeability to albumen, increasing π i , with a contribution of interstitial protein concentration released from lytic tumours so that, in a steady state, π c and π i equilibrate (Fig. 2c) . The result is a progressive decrease in fluid reabsorption. The inflow pressure is already reduced due to high vascular resistance so that P c = P i . Hence there is progressive diminution of flow from the vascular input across the tumour to the venous outflow. The final outcome is central necrosis.
MFT increases the inflow pressure and removes the intravascular protein (Fig. 2d ). The initial P c is increased (by 10 mm Hg) and the extravascular protein augments the outward chemotherapy flux both improving delivery and increasing interstitial pressure. Chemotherapy cannot be resorbed (venous π c = 0) and with the increase in venous capillary pressure, complete retention is achieved.
Vascular isolation mass cell transfer
There have been recent advances in stem cell biology with almost unlimited application in degenerative and cancer therapies [25] . The major barriers to successful therapy relate to delivering adequate cell concentrations, cell selection, endothelial transmigration time and reticuloendothelial attack. Pulmonary and non-target sequestration [26] present major obstacles for cell concentrations during IV delivery whilst the intra-arterial method appears superior in the delivery of stem cells intracerebrally [27] . Local infusions, intraarticular, intraperitoneal and intracerebral [27] methods suffer from anatomical barriers to develop adequate blood supply [28] . Vascular targeted isolation with inflow/ outflow control, removal of red blood cells and protein with circulatory arrest and complete segment replacement with cell suspensions addresses some of these issues. Pre-infusion ischaemia increases hydraulic conductance, the endothelial cell shear forces are non-existent, stem cell endothelial trans-migration times are improved by the higher ΔP without the need for selectins, integrins and cell adhesion molecules. All concentration and infusion repeatability is essentially unlimited with massed cell transfer.
Radiological catheter superselection
The closer the infusion site to the tumour bed the greater the benefit from the mass ratio of the tumour to the whole-body mass. Similarly, the less normal tissue is perfused, the less local chemotherapy toxicity. Table 3 summarises the relative mass ratio advantage of superselection compared to total body infusion. The vascular resistance is related to the conduit tube length (L) defined by the distance from the point of infusion origin to the tumour vasculature and this concept is defined in Poiseuille's law.
Protection of normal structures
The aim of avoiding chemotherapy toxicity to normal surrounding structures is similar to that of radiotherapeutic shielding. In particular, vascular shielding can be achieved via utilisation of the normal vasculature response to appropriate neurohumoral and thermal stimuli. Tumour vessels are much less reactive to physiological stimuli. The duodenal branches of the gastroduodenal arteries supplying chemosensitive duodenal mucosa exemplify the problem in the treatment of carcinoma of the head of the pancreas. The superselected infusion is often either via the gastroduodenal or inferior pancreaticoduodenal arteries [34] [35] [36] . Trans-gastric duodenal balloons inflated with cold water at pressures beyond the infusion pressure may act to minimise the chemotherapeutic effect on the duodenal mucosa. This concept would be similar to the use of Sengstaken-Blakemore tubes to control the bleeding of oesophageal varices [37] . Similarly, for infusions in the pelvis, balloons placed in the rectum, vagina and bladder at elevated pressures may protect the sensitive mucosa of these organs during chemotherapy infusions. Tourniquets on limbs, distal to a tumour target are simple adjuvant techniques to protect normal structure. Multicatheter access via the universal access system allows additional balloon inflow obstruction to neighbouring or collateral normal structures. In locoregional treatment of breast cancer, the distal branches of the internal thoracic artery were embolised to avoid unwanted perfusion of the abdominal wall [38] .
Increased lymphatic perfusion
The combined effect of high MFT, ischemia and hyperperfusion is to dramatically increase the volume of interstitial fluid [39] . As the tumour lymphatics are often hypoplastic and may be blocked by the tumour, the lymphatics of normal surrounding tissue are recruited to compensate [40] . A serendipitous effect may be the chemotherapy is thence directed to the local lymph nodes in a relatively efficient mechanism treating possible metastatic lymph nodes (Fig. 3) .
Minimal wall shear stress (flow arrest) (τ = 0)
Simultaneous inflow and outflow obstruction essentially reduces the intravascular fluid transit velocity to zero; hence the wall shear stress approaches zero. There is a known inverse relationship between shear stress and permeability [41] .
Time compression
In the pilot study [13] the aim of MFT was to reduce a 3 month chemotherapy cycle to 3.5 weeks with similar total doses of oxaliplatin. The aim was essentially achieved with minimal side effects although all patients had been heavily pre-treated with oxaliplatin and some had existing grade 3 peripheral neuropathy. As well as quality of life consideration, an early assessment of tumour sensitivity to a therapeutic regime may initiate a pre-emptive alternate therapeutic approach [13] . There are also molecular drivers favouring compression of treatment intervals. There is little anti-neoplastic activity beyond 16 h with oxaliplatin [42] . Many neoplastic cells divide every few days (e.g. Hela cells divide every 48 h) and cells not dividing or damaged may have time to mutate between treatments essentially leading to resistance. The rationale of this approach is based upon the dual effect of chemotherapeutic particles. The particles cause arterial obstruction thereby creating ischemia and the elution of chemotherapy contained within the embolic particles resulting in the apoptosis of the targeted cancer cells [43] [44] [45] [46] . Physiologically, lodgement of an arterial embolus occurs when the diameter of the embolus exceeds the diameter of the conduit. This often occurs at bifurcations where there is a rapid change in diameters. In the short term, the immediate result is ischemia distal to the particle, creating a pressure gradient and hence initiating an increase in collateral flow. The area of necrosis is surrounded by a viable but hypoxic area or "umbra". Proximal and distal propagated thrombus complicate the distribution of necrosis and cell viability (Fig. 4a) .
The distribution of TACE in large solid tumours is suboptimal due to the intrinsic chaotic vasculature of the neoplasia (Fig. 4b) . The diameter changes are often not at bifurcations but due to stenosis and dilatations within non-branching vessels. Even if proximal thrombosis can be avoided, chemotherapy delivery by a drug eluting bead would require diffusion retrograde to the next collateral [47, 48] (Fig. 4b) .
As the oxygen availability is the most important determinant of all cell viability [16] the relative diffusion capability of oxygen and the chemotherapy contained within the bead is an important consideration. Oxygen is fat soluble and passes through membranes rapidly. The haemoglobin molecule at low partial pressures has seventy times the concentration of dissolved gas. The high metabolic rate of tumour cells creates a significant gradient. In contrast, a therapeutic agent has to contend with very low flow, relatively high molecular weight as well as the intrinsic microvascular barriers. In addition, the hypoxic environment induces a switch from mitochondrial energy to glycolysis [16, 49] with induction of the self-preservation master gene (hypoxic induced factor) responsible for the upregulation of > 100 enzymes. The end result is viable tumour cells with little chemotherapy effect.
Suggested combination of TACE and Isolation MFT
Multicatheter access from the access device adds flexibility to the management of hepatobiliary neoplasms. As the catheter delivering the TACE is already in situ, pre-treating the induced "umbra" with MFT is a simple extension. In addition, delivering the TACE at suprasystolic pressures with venous obstruction addresses the concentration and microvascular barriers. Follow up MFT is possible to address post-necrotic neovascularisation.
This treatment regime can be used to potentiate selective internal radiation therapy (SIRT) [50, 51] . The radioactive compounds such as Yitrium-90 are lobar injections and selection is related to the increased blood supply of the tumours. However, many tumours are hypovascular or normovascular and therefore is very difficult for the radioactive compounds to reach the tumour. A single photon emission computedtomography (SPECT) scan performed 24 h after the initial injection can be utilized to indicate areas of Y90 concentration within the liver. TACE, MFT and an additional round of SIRT that then be used to selectively treat areas that were not treated or had suboptimal treatment (Fig. 4c) .
Cholangiocarcinoma
The prognosis for patients with inoperable intrahepatic or perihilar cholangiocarcinomas is bleak with median overall survival reported to be 10.0-14.2 months and 8 months respectively [52, 53] . Successful delivery of therapeutic doses of chemotherapy to these lesions is often difficult to achieve due to the complex vascular anatomy of the bile ducts. The blood supply to the bile ducts is primarily the peribiliary plexus [54] . These vessels, combined with the arteriolar portal connections, have a special function in modulating the blood flow of the hepatocytes between the hepatic artery and portal venous inflow [54] . The normal gradient between the two systems is 90 mm Hg from the hepatic artery to 5-7 mm Hg in the portal vein. The functional blood flow mediator is the hepatic artery buffer response (HABR). A decrease in blood volume in the portal venous flow results in the activation of the HABR creating a shunt into the portal venous system. This response is moderated by nitric oxide, adenosine and to a lesser extent carbon monoxide. Sensory innervation and sensory hormonal release also play a part [54] .
Application of vascular superselection and MFT
Obstruction of the portal blood flow via intestinal shutdown [13] activates the HABR which increases the delivery of active agent directly into the peribiliary plexus [54] .
Irinotecan and its active metabolic derivative SN38 are significantly bound by red cells and plasma [55, 56] ; 30-68% and 99% respectively ( Table 2) . Direct infusion into the affected segment improves the therapeutic advantage related to the mass ratio of the segment compared to the total body mass (Table 3) . Systemic leakage is counted by the binding of blood. Importantly SN38 is 50% secreted in the biliary tree. Chemotherapy retention is aided by tumour obstruction of the biliary tree. Other formulations appear to gradually be improving prognosis [57] [58] [59] all of which can be delivered via MFT.
Pelvis
The pelvic vasculature in particular represents an opportunity to deploy MFT. Although incidence rates have declined since 2007, prostate cancer is now the most common male neoplasia [60, 61] . Standard treatment is ablative surgery, which may result in a number of unwanted complications including urethral structure, urinary incontinence (stress, urgency, overflow and continuous), erectile failure and sterility [62, 63] . Radiotherapy can also result in undesirable side effects such as haemorrhagic prostatitis, cystitis, erectile incontinence and a relatively prolonged course of treatment [64] .
The blood supply of the prostate is bilateral via cranial and caudal prostatic arterial branches of variable origin from the internal iliac arteries. Radiological isolation, cannulation and embolization has been demonstrated in the treatment of benign prostatic hypertrophy [65] . However, there are some anatomical challenges associated with MFT. The pelvis has an extensive collateral arterial and venous circulation. Control of these collaterals is essential for delivery and retention of chemotherapy as well as removal of the plasma proteins essential for creation of beneficial oncotic gradients. The close proximity of the bladder and rectum with their relatively sensitive mucosa adds an extra complexity to successful treatment. In contrast, there are considerable advantages associated with isolation MFT. As the prostate has a small mass (Table 3) , the progress of treatment is relatively easy to follow with clinical examination, prostate specific antigen estimation and imaging. Collateral vessels can also be embolised by the same vascular access system and the treatment can be repeated (Fig. 5) . Protection of the rectal mucosa with a pressure monitored transrectal balloon with thermal control should also be considered.
Head and neck neoplasia
The tumour biology, anatomical location, vascular supply of head and neck tumours represent an opportunity for vascular isolation: they are often bulky exophytic masses with metastases limited to lymph nodes, the primary lesion is prone to causing significant local complications such as airway obstruction or infection [9] , lesions often have a visible component so that the progress of therapy can be monitored and the mass of the tumour is often small compared to the total body mass.
The concept of tumour isolation has been developed over many decades with gradual technological improvements such as the microcatheter and co-axial double balloon system [66, 67] which aid chemotherapy localisation and delivery. Adjunct radiotherapy has become much more refined and specific [68] . However, this treatment modality is not without its drawbacks: implantable trans-arterial catheters become infected and thrombosed, recirculation of chemotherapy results in systemic side effects, and contralateral collaterals from the external carotid branches and intracranial branches allow alternate untreated areas of tumours to divide and multiply [69] . The haemodynamic microvascular barriers to delivery are also not addressed by current technology. Isolated MFT may provide some additional improvement to the current treatment protocol. Cannulation from a single access point from the groin into the feeding vessels can provide two levels of obstruction minimising collateral flow. The degree of vascular isolation and cross feeding can be monitored by simultaneous cannulation and pressure transduction of the contralateral external carotid artery. Removal of plasma and red blood cells from the area allows delivery of the active agent directly into the tumour. For example, approximately 90% of cisplatin is red cell and plasma bound with neutralisation by the plasma with systemic leakage (Table 2) . Ischemic time can be assessed by a measurement of facial skin flow. Drug retention is promoted by outflow obstruction; real time ultrasound obstruction of a common facial vein via direct probe compression can be augmented via PEEP, Trendelenburg, or direct endovenous balloon obstruction.
Central nervous system (CNS)
Both primary and secondary neoplasms of the CNS represent a special opportunity for vascular isolation MFT delivery of chemotherapy. There are now commercially available sophisticated superselective microcatheters used for treatments for other cerebral disorders, such as embolic stroke [70] , intracranial aneurysms [71] and intracerebral embolic procedures for tumours [72] . There are also several intrinsic protective mechanisms insulating the normal brain from external deleterious forces; specifically, the myogenic vascular autoregulation for stabilisation of blood pressure, focal pressure buffering by the cerebrospinal fluid (Pascal's Law) and the blood brain barrier.
The forces governing intracerebral fluid transfer are greatly modified by the blood brain barrier. The cerebral vascular endothelial hydraulic conductance (permeability) K p is much lower for stabilisation of the cerebral fluid flux in response to systemic variation. The normal endothelium is impermeable to protein and low molecular solutes (Na, Cl) and thus the Staverman resorption coefficient is high for these solutes. Mannitol and hypertonic saline exert an osmotic force which decreases both intracellular and IFP, while protein induced oncotic pressure is negligible. In contrast tumours have a porous vascular endothelium similar to the microvascular architecture of most solid tumours. This has been confirmed by a gadolinium MRI [73] showing increased hydraulic tumour conductance and increased permeability to Na and Cl.
The physiological differences between tumour and brain are highlighted in Table 4 . Therefore in MFT delivery, the protein induced osmotic forces become much more relevant; hence intracerebral chemotherapy delivered to tumours is automatically self-selected even if delivered more proximally in the vascular system (extracranial internal carotid artery). Mannitol will have significant action only on normal cerebral tissue. Induced filtration pressure of the tumour is transmitted equally by the cerebrospinal fluid throughout the cranium (Pascal's Law) improving the safety factor. Cerebral autoregulation [74] also protects local hypertension of the tumour interface. The mass ratio of the tumours compared to the total body mass is very high (Table 3) and can be delivered locally provided systemic contamination can be kept to a minimum.
However, there are many further confounding factors in the treatment of cerebral neoplasia. The warm ischaemic time of cerebral tissue is short which limits the total chemotherapy transfer across the endothelium. This can be monitored by the patient under local anaesthetic by command response techniques and also predicted by the assessment of the carotid stump pressures [75, 76] . Carotid endarterectomy performed under local anaesthetic requires extracranial carotid ischaemia of at least 20 min. Stump pressures > 50 mm Hg are rarely associated with any untoward neurological events. However these patients were having the procedures often for haemodynamically significant lesions which would encourage crossover cerebral flow [75, 76] . Neoplastic cells may be found in remote portions of the brain perhaps related to the intracerebral lymphatic flow [77] . Also, treatment via super selected microcatheters require anticoagulation which carries the associated risk of intra-tumour and intracerebral haemorrhage. 
The breast
Many of the targeted concepts have been developed by Stephens and others [78] [79] [80] [81] . Repetitive superselective infusions, blood flow distribution techniques and combinations with radiotherapy have shown good results in Stage III carcinomas [78] . However, the limiting factors have been systemic side effects related to recirculation during intra-arterial infusions [38] . MFT allows control of collateral arterial inflow, oncotic pressure, viscosity and outflow for chemotherapy retention as well as time compression and ease of repeatability.
The superficial location of the breast allows monitoring and modulation of therapy. The tumours and nodes are often palpable and the interstitial flux of fluid visible during therapy and measurable by simple pressure transduction into the interstitial breast tissue with a small cannula. Injectable intra-arterial coloured dyes can indicate the distribution of the arterial inflow to a particular tumour [38, 79] . The anatomical blood supply of the breast allows control of the collateral vessels to ensure adequate removal of red cells and protein from the infused area. The lymph nodes can be perfused by infusions of chemotherapy into normal areas surrounding the tumour with normal lymphatics which ascend to the draining nodes. This technique provides specific chemotherapy treatment to neoplasia within the draining lymph nodes (Fig. 3) . The venous outflow is relatively easy to control with long endovascular balloon catheters within the subclavian axillary and brachial venous system. More proximal inflation of these balloons into the jugular confluence also controls the lymphatic flow via the main lymphatic ducts entering into the venous system. The breast tissue itself exhibits a very long ischaemic time which allows extra retention of chemotherapeutic agents. On the negative side, the perforating intercostal arteries provide a small alternate collateral supply which are difficult to control. The use of PEEP is also advisable to modify this systemic leakage via the intercostal perforating veins. The technique has been described previously by the authors [82] . 
The lung
The biology of lung tumours varies somewhat according to their type: primary or secondary. Primary tumours have a large proportion of their arterial blood supply via the bronchial vessels (60%). Half of all secondary tumours tend to have blood supplied via the pulmonary artery (PA) alone while a third have a dual supply and the remainder via the bronchial vessels [83] . The filtration mechanics of the lung parenchyma are substantially different to systemic circulation. The pulmonary artery blood pressure is 25/10 mm Hg. The capillary hydrostatic pressure (P C ) is 13 mmHg and the venous pressure is 6 mmHg. The resorption co-efficient (σ) is decreased to allow nutrient exchange. The pathophysiological response to PA obstruction during MFT delivery of chemotherapy is similar to that of a pulmonary embolus from a proximal deep venous thrombosis. There is considerable neuroregulated arterial and venous vasoconstriction distal to the embolic site with shunting of the deoxygenated blood into the residual aerated pulmonary segments. This response is protective in order to maintain adequate total body gas exchange. Therefore, there is a need to deliver chemotherapy at supra-systolic PA pressures in order to overcome the intrinsic high vascular resistance within tumours.
Various treatments for the targeting of lung neoplasia has been described [84] including chemoembolisation with microspheres combined with mitomycin C: 52 patients with 106 metastases for secondary tumours with encouraging results [85] . Isolated lung perfusion with metastatic sarcoma has had mixed results [86] while improved results were obtained with high dose hyperthermic cisplatin infusions [87] . The technical challenges associated with isolated lung perfusion relate to difficulty with repeatability and particularly the requirement to treat multiple tumours simultaneously. Additional challenges relate to bronchial artery tortuosity and dual supply from the pulmonary artery.
There is also a paucity of data on chemotherapy response rates combined with other modes of therapy including surgical metastectomy and radiotherapy. MFT is simple, repeatable and isolated pulmonary segments can be individually targeted with supra-systolic pressures on the arterial side and outflow pressures increased with PEEP. Diffuse metastases can be addressed one segment or lobe at a time.
Pancreas
Pancreatic neoplasia is notoriously difficult to treat due to certain intrinsic biological characteristics. The tumours are desmoplastic. Also, most of the tumour is relatively hypoxic and is resistant to chemotherapy, radiotherapy, and immunotherapy [88] . The clinical presentation is often delayed with local spread into the duodenal wall, the lymphatics and perineural involvement [89] . Pancreatic duodenal resection (Whipple procedure) affords minimal prospect of cure [90] .
If the major vessels are not involved, a 43.1% long term survival rate can be expected [91] . However, should invasion of the splenic artery and vein occur, the five year cure rate drops to 13.8% if the affected vessels are resected [91] . These presentations are defined as "borderline" presentations, typically characterised by obstructive venous involvement of the portal vein or superior mesenteric vein with distortion, occlusion or narrowing of the vein. More insidious complications include encasement of the gastroduodenal artery extending to include the hepatic artery with either short segment encasement or direct abutment without extension to the coeliac axis or abutment to the superior mesenteric artery < 180°of the vessel wall's circumference [92] . Other protocols are used for patients with borderline resectable cancers. The aim of chemotherapy is to convert unresectable tumours to ones that are resectable or borderline tumours to a resection that is perhaps less challenging. Substantial progress has been made with modern chemotherapy [93] .
Pancreatic neoplasia has specific vascular and anatomical features which are conducive to MFT targeting. The size of the tumour is often 3-4 cm which represents an advantage of 5000 to 1 in terms of mass ratio to the total body mass (75 kg). Lymphatic and interstitial spread is particularly important in this tumour type which is amenable to MFT techniques. Super selection of the gastroduodenal vessels distal to the right gastroepiploic vessel provides a direct infusion conduit into the pancreatic head. Also, infusions from the inferior pancreaticoduodenal arteries are an alternative approach utilizing a microcatheter. The duodenum with its sensitive duodenal mucosa is adjacent to the tumour in many cases and therefore warrants protection from the deleterious effects of chemotherapy delivery. This can be afforded utilizing a hypothermic transgastric duodenal balloon system which can be pressure monitored to compress and vasoconstrict the vascularity of the mucosa (Fig. 6 ).
Advantage calculation compared to IV
The approximate advantage over IV in a particular anatomical site (R a ) is given by the product of the target mass ratio (m TB /m t ; total body mass divided by tumour mass), the advantage of plasma binding (P b ), the viscosity advantage (μ a ), the MFT advantage (MFT a ), and the number of repeat treatments (n) as shown in Eq. 6.7). The MFT a can be calculated by the improvements in the delivery pressure in MFT as shown in Fig. 2a-b . On the arterial side, increasing perfusion by 10 mmHg and removal of proteins creates an outward arterial flux (J Va ) of 50 mmHg (Fig. 2b) compared to the normal IV case of 12 mmHg (Fig. 2a) ; just over a four-fold increase in prefusion. On the venous side, 16 mmHg of PEEP and increased perfusion of 4 mmHg gives a total J Vv of 36 mmHg in the absence of protein compared to −12 mmHg in the normal IV setting. This flux is a about a four-fold increase in the retention. The total MFT a would be the sum of the advantage on the arterial and venous side achieved (MFT a = 4 + 4 = 8). Substituting all these variables into Eq. (1) yields a total advantage of 186,528 times that of IV delivery.
Conclusion
The combination of modern radiological techniques and universal repeatable access has the capability of controlling many of the known variable parameters affecting targeted delivery of therapeutic agents: specifically the flux (J v ); cross sectional area (A); hydraulic conductance (K p ); capillary inflow and venous outflow pressures (P c ); intravascular oncotic pressure (π c ); flow (Q); red cell mass; viscosity (μ); length of conducting tube (L); wall shear stress (τ); time of infusion; particle velocity; partial pressure of oxygen; temperature; time between treatments; maximum delivered concentration (C max ); total AUC;
The four cornerstones of vascular isolation MFT are:
1. Targeted, hypertensive, hypo-oncotic, ischaemic superselected chemotherapy delivery without plasma and red cell binding. 2. Retention of chemotherapy via tumour venous outflow obstruction, hypo-oncotic induced reabsorption inhibition. 3. Time compression; rapid targeted repetition to minimise tumour temporospacial reorganisation and mutation.
4. Protection of normal structure via microvascular shielding.
The individual organ vascular anatomy and specific tumour biology determines the optimal approach to endovascular isolation and the tumouricidal weapon to be delivered. From a pathophysiological perspective, standard IV therapy has the optimal impact on smaller tumours with "normal vasculature" while MFT is more suited to larger tumours with chaotic microvascular architecture. The combination is inherently complementary but yet to be tested in depth.
